Safety, Tolerability and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With NAFLD
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the
safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant
recipients with NAFLD.